A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (NCT02655016)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
🩺 Plain-English Summary (8th-Grade Level)
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Tempe, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (116 Sites)
Showing the first 25 of 116 sites.
- GSK Investigational Site — Tempe, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — Santa Rosa, California
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Savannah, Georgia
- GSK Investigational Site — Geneva, Illinois
- GSK Investigational Site — Indianapolis, Indiana
- GSK Investigational Site — Indianapolis, Indiana
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Covington, Louisiana
- GSK Investigational Site — New Orleans, Louisiana
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Rockville, Maryland
- GSK Investigational Site — Burlington, Massachusetts
- GSK Investigational Site — Grand Rapids, Michigan
- GSK Investigational Site — Minneapolis, Minnesota
- GSK Investigational Site — Springfield, Missouri
- GSK Investigational Site — Neptune City, New Jersey
- GSK Investigational Site — Harrison, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Neoplasms
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Anchorage, Alaska
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer — Durham, North Carolina
- Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — New York, New York
- Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — Little Rock, Arkansas
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Randwick, New South Wales
Explore by condition: All Ovarian Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.